Physician

Shukri A Osman, MD

According to 2025 Medicare claims, Shukri Osman, MD (NPI: 1649248717) practices nephrology in the Kahului-Wailuku, HI market, with the plurality of this provider's patient population coming from Maui, HI. This provider's primary affiliated billing organization is NORTHWEST RENAL CLINIC, INC. (NPI: 1528036662; TIN: 930751490) and primary practice location at 96793-2443.

Osman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 221 traditional Medicare patients, billed 2,067 HCPCS/CPT codes, and received $148,975 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 745 prescription claims across 169 beneficiaries totaling $227,507 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 66 claims. Open Payments data shows 7 records totaling $152. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $117,261 to $148,975. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $229,757 and ending at $227,507. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	341	3,974	$117,261
2016	318	2,844	$118,504
2017	253	3,359	$108,079
2018	257	1,676	$99,860
2019	251	1,950	$94,119
2020	309	1,817	$104,934
2021	300	1,523	$118,733
2022	219	1,971	$157,236
2023	183	1,551	$152,770
2024	221	2,067	$148,975

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	178	2,132	$229,757
2016	190	2,175	$329,320
2017	193	1,900	$239,961
2018	181	1,577	$146,626
2019	200	1,804	$148,218
2020	211	1,919	$190,934
2021	232	1,116	$143,286
2022	196	773	$139,700
2023	162	762	$190,270
2024	169	745	$227,507

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	23	531	$28,243
2016	66	744	$47,440
2017	72	674	$27,747
2018	60	651	$30,947
2019	63	653	$21,542
2020	82	744	$25,782
2021	65	595	$15,334
2022	N/R	100	$1,297
2023	N/R	N/R	N/R
2024	N/R	66	$854

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	56	65	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	48	89	$87
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	78	235	$60
90935	Hemodialysis procedure with physician evaluation	42	124	$55
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	45	67	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	34	2,514	$46,434
Ozempic	Semaglutide	36	1,628	$35,742
Jardiance	Empagliflozin	15	870	$16,782
Sevelamer Carbonate	Sevelamer Carbonate	41	3,330	$9,423
Calcium Acetate	Calcium Acetate	15	729	$1,717

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	33	$401
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	19	$189

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$152	Ardelyx, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shukri A. Osman, MD?

Tedicare shows public-source Medicare data for Shukri A. Osman, MD (NPI 1649248717), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shukri A. Osman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shukri A. Osman, MD?

Shukri A. Osman, MD is linked to NORTHWEST RENAL CLINIC, INC. (billing NPI 1528036662) in the available physician profile data.

Does Shukri A. Osman, MD have Open Payments data?

Shukri A. Osman, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.